Ondansetrón Accord (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón Accord, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetrón Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetrón Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of the vomiting episodes in patients receiving highly emetogenic chemotherapy. - Radiation‑induced vomiting and nausea : The ...